reports
Cytokinetics Inc: 3 directors
Three Directors at Cytokinetics Inc sold 13,906 shares at between 48.670USD and 50.000USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Cytokinetics Presents New Data Related to Aficamten at the European So...
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten Company...
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the...
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that primary results from MAPLE-HCM (Met...
Cytokinetics to Participate in September Investor Conferences
Cytokinetics to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi’s 2025 BioPharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025 at 2:30 PM Eastern Time in Boston, MA.2025 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 3, 2025 at 11:00 AM Eastern Time in Everett, MA.Cantor Global Healthcare Conference 2025:...
Cytokinetics Announces Five Presentations Related to Aficamten at the ...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced ...
Cytokinetics Names Jim Daly to Board of Directors
Cytokinetics Names Jim Daly to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. “Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies,...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of common stock and 70,879 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 46 employees, whose employment commenced in July and August 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the fir...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Cytokinetics Reports Second Quarter 2025 Financial Results and Provide...
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line Session at the European Society of Cardiology Congress 2025 ~$1.0 Billion in Cash, Cash Equivalents and Investments as of June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)...
Cytokinetics to Announce Second Quarter Results On August 7, 2025
Cytokinetics to Announce Second Quarter Results On August 7, 2025 SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at or ...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first a...
Cytokinetics Announces Five Presentations Related to Aficamten at the ...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at th...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first a...
Cytokinetics Announces Call For Proposals For Annual Corporate Giving ...
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 4th, 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, diversity in ...
Cytokinetics to Participate in the Jefferies Global Healthcare Confere...
Cytokinetics to Participate in the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at . The webcas...
Cytokinetics Presents Additional Data Related to Aficamten at the Euro...
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first ann...
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Bi...
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA. “CLIMB was born out of our vision t...
Cytokinetics Announces Positive Topline Results From MAPLE-HCM
Cytokinetics Announces Positive Topline Results From MAPLE-HCM Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as...
Cytokinetics Announces Four Upcoming Presentations at the European Soc...
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking Science Presentations Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.